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We evaluated the short-term of 0 to 90 days and the longer term, up to 12.7 years, mortality 
for patients undergoing primary total hip replacement (THR) in Denmark in comparison to 
the general population. Through the Danish Hip Arthroplasty Registry we identified all 
primary THRs undertaken for osteoarthritis between 1 January 1995 and 31 December 2006. 
Each patient (n = 44 558) was matched at the time of surgery with three people from the 
general population (n = 133 674). We estimated mortality rates and mortality rate ratios with 
95% confidence intervals for THR patients compared with the general population. There was 
a one-month period of increased mortality immediately after surgery among THR patients, 
but overall short-term mortality (0 to 90 days) was significantly lower (mortality rate ratio 
0.8; 95% confidence interval 0.7 to 0.9). However, THR surgery was associated with 
increased short-term mortality in subjects under 60 years old, and among THR patients 
without comorbidity. Long-term mortality was lower among THR patients than in controls 
(mortality rate ratio 0.7; 95% confidence interval 0.7 to 0.7). 
Overall, THR was associated with lower short- and long-term mortality among patients 
with osteoarthritis. Younger patients and patients without comorbidity before surgery may 
also experience increased mortality after THR surgery, although the absolute risk of death is 
small.
Total hip replacement (THR) is widely consid-
ered to be cost-effective and safe.1,2 However,
only a few studies have reported mortality fol-
lowing primary THR in a population-based
sample and made comparisons with the corre-
sponding general population. Mortality has
been reported to be higher for THR patients
than that of the corresponding population in
the first 30 days after surgery, but variously
similar or lower mortality has been reported
for the period between 60 and 90 days.3-5
Long-term mortality has been reported to be
lower than that of controls.4
Comorbidity is a well-established prognos-
tic factor for many diseases as well as for
adverse outcomes after medical interven-
tions.6-8 The available literature on the impact
of comorbidity on short- and long-term mor-
tality among THR patients is limited.3,9-13 It is
well accepted that THR is recommended for
patients with little or no comorbidity, as
adverse outcomes increase as the number of
comorbid conditions rises.5 One study exam-
ined the impact of age and gender on short-
and long-term mortality among THR patients
relative to the controls from the general popu-
lation.4 It was observed that there was an
increase in long-term mortality with decreas-
ing age at operation, but this pattern could not
be confirmed for short-term mortality. An
important question is how much THR surgery
affects mortality in selected healthy and young
patients compared with corresponding con-
trols who have not required THR, both in the
short and the long term.
Vascular disease has been reported as the
most common cause of death among THR
patients in general during the first 60 and
90 days post-operatively, and for up to four
years after surgery.9-11 However, cause-specific
mortality among THR patients has not been
well studied. In order to clarify these issues, we
conducted a nationwide, population-based
study on the short- and long-term mortality
among THR patients with osteoarthritis in
relation to age, gender and comorbid condi-
tions before surgery.
Patients and Methods
Data sources. We used medical databases in
Denmark to identify patients who have under-
gone THR and to ascertain their status during
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the subsequent years. The Danish Hip Arthroplasty
Registry14 holds data on all patients with a primary or revi-
sion THR performed in Denmark since 1 January 1995. All
45 orthopaedic departments in Denmark, including five
private hospitals, report to the registry. Pre-, peri- and post-
operative data are collected by the operating surgeon using
a standardised form. The Danish Civil Registration System
is a national registry of all Danish residents which has
maintained records regarding status and residence for the
entire population since 1968. The Danish National Regis-
try of Patients has kept data on all acute care hospital
admissions since 1977 (and since 1995, for all hospital spe-
cialist outpatient visits), including the dates of admission
and discharge, and up to 20 discharge diagnoses classified
according to the International Classification of Diseases15
(Eighth edition until the end of 1993, Tenth edition there-
after). The Danish Registry of Causes of Death has kept
information on causes of death on all Danish citizens who
have died since 1970. A death certificate must be filed for
every person who dies; it is completed by the physician with
the most accurate knowledge of the events that led to death.
Causes of death are coded according to the International
Classification of Diseases (Tenth edition) as the underlying
cause of death and up to three additional immediate causes.
All Danish citizens are assigned at birth a unique ten-digit
personal identification number encoding age, gender and
date of birth. This permits unambiguous linkage between
all Danish medical databases.16
Study population. Using the Danish hip registry, we identi-
fied all primary THR patients with osteoarthritis operated
on during the period between 1 January 1995 and
31 December 2006. Only the initial THR recorded in the
registry was included. There were 44 558 patients in the
final study population.
Each THR patient was matched by year of birth and gen-
der at the time of surgery with three people from the gen-
eral population who were alive on the date of that patient’s
surgery, irrespective of their previous THR history. These
controls were randomly sampled using the Danish Civil
Registration system. Sampling was with replacement, so an
individual could be chosen as a control more than once. In
all, 4663 persons were chosen as a control twice, 137 were
chosen three times, and four people were chosen four times
for different THR patients. Thus 133 674 age- and gender-
matched controls from the general population were
included in the final study population.
Comorbidity. For each THR patient and control, we identi-
fied all primary and secondary discharge diagnoses for all
hospital admissions since 1977, and hospital specialist out-
patient visits since 1995 prior to the time of surgery. Using
these data, we computed the Charlson comorbidity index
score.7,17 This index, originally developed and validated for
the prediction of short- and long-term mortality in patients
admitted to departments of internal medicine,17 includes
19 major disease categories, including cardiovascular, cere-
brovascular, chronic pulmonary, liver, renal and gastro-
intestinal diseases, diabetes, and solid and haematological
tumours. Admissions from each category are weighted as
one, two, three or six points, and the score is the sum of
these weightings. We classified the patients and controls
according to three levels of comorbidity: low (those with a
score of zero prior to the time of surgery or index date);
moderate (those with one or two points); and a high index
(those with more than two points).18
Apart from studying the effect of three different categories
of Charlson comorbidity index on the association between
THR and mortality, we aimed to study the prognostic effect
of specific comorbidities. We therefore also classified the
THR patients and controls according to their prior hospital
admission with cardiovascular diseases (myocardial infarc-
tion, congestive heart failure, peripheral vascular disease
and/or cerebrovascular disease), diabetes and cancer.
Mortality. The outcomes studied were short-term mortality,
within 90 days after surgery, and subsequent longer-term
mortality. All subjects were followed until 16 September
2007, when the information on vital status and cause of death
was obtained. The following causes of death were examined:
myocardial infarction, congestive heart failure, venous
thromboembolism, pneumonia, stroke, upper gastrointesti-
nal ulcers and any cancer. Both THR patients and controls
could have multiple causes of death on the death certificate.
Statistical analysis. We computed all-cause mortality rates
as the number of deaths within a specific subject category
divided by the number of person-years at risk within the
same group of subjects, expressed per 100 000. Mortality
rates were calculated separately for THR patients and con-
trols within groups defined by gender, age in the ranges ten
to 59, 60 to 69, 70 to 79 and > 80 years. The Charlson
comorbidity index was calculated using the categories
listed above and their specific comorbid diagnoses (cardio-
vascular diseases, diabetes and cancer). We used Cox’s pro-
portional hazards regression to estimate all-cause and
cause-specific mortality rate ratios and 95% confidence
intervals (CI), both crude and adjusted for gender, age and
Charlson comorbidity index. As our preliminary analyses
indicated that the mortality rate ratios, adjusted for the
19 diagnoses included in the Charlson index, were similar
to those adjusted for the Charlson comorbidity index, we
presented estimates adjusted for the Charlson index. Anal-
yses were conducted for short-term mortality (0 to 90 days)
and long-term mortality (subsequent follow-up). We used
likelihood-ratio tests to test for heterogeneity. Additional
analyses were carried out to examine the attributable risk
by subtracting the mortality in the general population from
that in the THR patients.
Our preliminary analyses indicated that the mortality rate
ratios stratified by matched THR patient-control sets from the
background population did not differ from those that were
the result of the Cox model without stratification. Therefore,
all presented estimates were derived from the unstratified
Cox’s proportional hazards model. Log-log plots19 and
Schoenfeld residuals20 did not indicate deviation from the
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assumption of proportional hazards. All analyses were per-
formed using the Stata Statistical Software: Release 9.0 (Stata
Corp., College Station, Texas), and p-values < 0.05 were
taken to denote statistical significance.
The study was approved by the Danish Data Protection
Agency.
Results
Study population. THR patients with osteoarthritis had
slightly fewer comorbid conditions on previous hospital
admissions than did controls; the proportion with one or
more non-musculoskeletal comorbid diagnoses at the time of
surgery was 30% in THR patients versus 33% in controls (p
< 0.001). Including musculoskeletal diagnoses, the propor-
tions were 32% vs 34% (p < 0.001) (Table I). However, this
pattern varied according to age and gender, being more pro-
nounced for subjects > 60 years and for women. In contrast,
among subjects < 60 years old the proportion of non-muscu-
loskeletal comorbid diagnoses was 17% vs 16% for THR
patients and controls, respectively (p < 0.001), and the pro-
portions with any comorbid diagnoses were 19% and 17%,
respectively (p < 0.001). THR patients had a lower preva-
lence of previous cardiovascular and chronic pulmonary dis-
ease, as well as diabetes, than controls. However, younger
THR patients had a slightly higher prevalence of these dis-
eases, in addition to inflammatory diseases, than controls.
Short-term mortality following THR (0 to 90 days). Over-
all short-term (90-day) mortality among THR patients with
osteoarthritis was low, lower than among matched controls
(mortality rate 7.5 (95% CI 6.7 to 8.4) vs 10.2 (95% CI 9.6
to 10.8) per 100 000, p < 0.001), corresponding to an
adjusted mortality rate ratio of 0.8 (95% CI 0.7 to 0.9) and
a negative attributable risk of 2.7 per 100 000 person-
years. However, in the 30 days after surgery, mortality was
higher among THR patients (adjusted mortality rate ratio
1.4 (95% CI 1.2 to 1.7)), decreasing thereafter so that the
cumulative mortality at 60 days was identical to that in
controls (adjusted mortality rate ratio of 1.0 (95% CI 0.9
to 1.1)) and subsequently became lower.
The relative mortality varied according to gender, age
and comorbidity. The reduction in overall 90-day mortality
among THR patients with osteoarthritis was confined to
women (adjusted all-cause mortality rate ratio 0.6 (95%
CI 0.5 to 0.8)); for men, short-term mortality was identical
among THR patients and controls (p < 0.001) (Table II).
The mortality rates at 90 days were lower for THR patients
than for controls for all the age categories except for the
youngest THR patients, and the absolute difference in rates
increased with age. THR patients < 60 years with osteo-
arthritis had an increased relative all-cause mortality within
90 days (adjusted mortality rate ratio = 2.1, 95% CI 1.1 to
3.7), which was in clear contrast to subjects > 60 years
(p < 0.001) (Table II). The same pattern was observed for
the 30-day and 60-day mortality, with the adjusted
mortality rate ratio for THR patients < 60 years being
5.5 (95% CI 2.2 to 15.6) and 2.7 (95% CI 1.4 to 5.5),
respectively, compared with controls of the same age. The
increase in relative mortality among patients < 60 years was
independent of comorbidity index.
The reduced 90-day mortality for THR patients was also
confined to individuals with a moderate or high Charlson
comorbidity index, in contrast to subjects with a low index,
who had a similar risk to those in the general population
(p < 0.001) (Table II). The adjusted relative mortality by
30 days and 60 days after surgery in those without prior
comorbidity was 2.1 (95% CI 1.5 to 2.9) and 1.4 (95% CI
Table I. Characteristics of patients with osteoarthritis who underwent total hip replacement (THR) and controls from the
general population
THR patients (n = 44 558) (%)
Population controls
(n = 133 674) (%)
Gender
Female 25 036 (56) 75 108 (56)
Male 19 522 58 566
Age (years)
10 to 59    7665 (17) 23 082 (17)
60 to 69 14 218 (32) 42 590 (32)
70 to 79 16 264 (36) 48 778 (36)
More than 80    6411 (14) 19 224 (14)
Charlson comorbidity index
Low 30 201 (68) 87 994 (66)
Moderate 11 756 (26) 35 812 (27)
High    2601 (6)    9868 (7)
Previous hospital admissions
Cardiovascular diseases    6023 (13) 21 529 (16)
Diabetes    1561 (3)    5817 (4)
Any cancer 4022 (9) 12 812 (10)
Hospitalisation with any of the 19 diagnoses included in 
the Charlson comorbidity index
14 357 (32) 45 680 (34)
Hospitalisation with any of the 19 diagnoses included in 
the Charlson comorbidity index, except for musculoskeletal 
diseases
13 442 (30) 43 678 (33)
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1.1 to 1.7), respectively, for THR patients compared with
controls also without comorbidities.
Long-term mortality following THR (90 days to 12.7 years).
During the maximum follow-up of 12.7 years, 94 410 sub-
jects were followed for no more than five years, 64 435 for
five to ten years, and 19 386 for ten years or more. In the
long term, THR patients with osteoarthritis had a lower
mortality than population controls. Thus, a total of 7731
(17.5%) THR patients with osteoarthritis died during
follow-up after 90 days (mortality rate 9.2 (95% CI 9.0 to
9.4) per 100 000 person-years), as did 29 820 (22.5%) con-
trols (mortality rate 12.4 (95% CI 12.4 to 12.7) per 100 000
person-years). The adjusted mortality rate ratio was 0.7
(95% CI 0.7 to 0.7) and the attributable risk was reduced by
3.2 per 100 000 person-years. The lower relative mortality
was seen in all subgroups, with the exception of individuals
< 60 years, among whom THR patients had a similar long-
term mortality as controls (mortality rate ratio = 0.9, 95%
CI 0.8 to 1.1) (Table II). Again, the mortality rates were
lower for THR patients than for controls in all age groups,
and the absolute differences increased with age.
Cause-specific mortality. THR patients with osteoarthritis
had increased 90-day mortality from myocardial infarction
and venous thromboembolism/pulmonary embolism than
matched controls, irrespective of age, gender and prior
comorbidity index (Table III). In contrast, short-term
cancer mortality was lower (adjusted mortality rate ratio
was 0.2 (95% CI 0.1 to 0.3)). THR patients with osteo-
arthritis had decreased long-term mortality due to all spe-
cific causes of death examined in our study (Table III), even
after adjustment for age, gender and comorbidity index.
Discussion
In this nationwide population-based cohort study we found
that THR in patients with osteoarthritis was associated with
lower short- and long-term mortality than in matched con-
trols. However, there was an increased short-term mortality
risk confined to younger patients (< 60 years old) and to sub-
jects without prior comorbidity noted on previous hospital
admissions and specialist outpatient visits. Patients undergo-
ing THR had an increased 90-day risk of death from myo-
cardial infarction and deep venous thrombosis/pulmonary
embolism, irrespective of age, gender and comorbidity index.
Mortality among THR patients has previously been
compared with that of the general population.3-5 Our find-
ings that overall mortality within 60 days of THR in
patients with osteoarthritis was about equal to that in the
underlying population, conflict with results reported by
Lie et al,4 who observed a 41% lower mortality. Possible
explanations for the differences are the selection of
patients for primary THR or differences in the definition of
a diagnosis of osteoarthritis between Denmark and
Norway. Both our study and that of Barrett et al3 found
that within 30 days of surgery mortality among THR
patients was increased, with a subsequent decline in
relative mortality over time. Lie et al21 recently reported a
small increase in mortality within 26 days post-operatively.
In contrast to our findings, Mahomed et al5 and Barrett et
al3 reported that the probability of dying did not
differ between THR patients and matched controls over
the 90-day period after surgery. However, these studies
included both patients with osteoarthritis and those with
rheumatoid arthritis, making comparisons difficult.
Table II. Mortality rates and mortality rate ratios (MRR) of total hip replacement (THR) patients operated on for osteoarthritis versus age- and gender-
matched controls from the general population
0 to 90 days 90 days to 12.7 years
Mortality rates* 
THR vs general 
population
THR, 
number 
deaths/N 
General 
population,
number 
deaths/N
Adjusted MRR† 
(95% CI)
Mortality rates* 
THR vs general 
population
THR, 
number 
deaths/N
General 
population, 
number deaths/N
Adjusted 
MRR† 
(95% CI)
Gender
Female   5.6 vs 9.8 127/25 036 658/75 108 0.6 (0.5 to 0.8)   8.5 vs 11.7 4080/24 909 15 957/74 449 0.7 (0.7 to 0.7)
Male   9.8 vs 10.8 171/19 522 565/58 566 1.0 (0.8 to 1.2) 10.1 vs 13.5 3651/19 351 13 863/58 001 0.7 (0.7 to 0.7)
Age (years)
10 to 59   2.8 vs 1.3   19/7665   27/23 082 2.1 (1.1 to 3.7)   2.3 vs 2.4   361/7646    1120/23 055 0.9 (0.8 to 1.1)
60 to 69   3.0 vs 4.8   38/14 218 185/42 590 0.6 (0.4 to 0.9)   5.0 vs 6.8 1400/14 180    5500/42 404 0.7 (0.7 to 0.8)
70 to 79   8.6 vs 11.8 125/16 264 514/48 778 0.8 (0.6 to 0.9) 11.8 vs 16.1 3614/16 139 13 825/48 264 0.7 (0.7 to 0.8)
≥ 80 20.4 vs 29.1 116/6411 497/19 224 0.8 (0.7 to 1.0) 22.8 vs 35.9 2356/6295    9375/18 726 0.6 (0.6 to 0.7)
Charlson comorbidity index
Low   4.3 vs 3.9 118/30 201 309/87 994 1.1 (0.9 to 1.3)   6.9 vs 8.2 4184/30 083 14 083/87 683 0.8 (0.7 to 0.8)
Moderate 12.9 vs 15.7 135/11 756 503/35 812 0.8 (0.7 to 1.0) 13.7 vs 20.2 2725/11 621 11 282/35 309 0.7 (0.6 to 0.7)
High 19.4 vs 47.2   45/2601 411/9868 0.4 (0.3 to 0.6) 23.1 vs 40.6   822/2556    4455/9457 0.6 (0.5 to 0.6)
Previous hospitalisations
Cardiovascular 20.9 vs 27.0 112/6023 517/21 529 0.8 (0.7 to 1.0) 17.8 vs 28.5 1661/5911    8454/21 012 0.6 (0.6 to 0.7)
Diabetes 18.7 vs 25.1   26/1561 130/5817 0.8 (0.5 to 1.2) 17.0 vs 27.0   391/1535    2107/5687 0.6 (0.6 to 0.7)
Any cancer 10.8 vs 32.1 39/4022 365/12 812 0.3 (0.2 to 0.5) 16.1 vs 24.7 1050/3983    4413/12 447 0.6 (0.6 to 0.7)
* per 100 000 person-years
† MRR, adjusted for gender, age and Charlson comorbidity index. As the MRRs adjusted for 19 diagnoses included in the Charlson index were similar
to MRRs adjusted for Charlson comorbidity index as such, we present estimates adjusted for Charlson index. All comparisons were between cases
and controls with the same characteristics, i.e. THR with diabetes before surgery were compared with controls with diabetes before surgery. N,
number of subjects; CI, confidence intervals.
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As in our data, an increased long-term relative mortality
after THR in patients younger than 60 years of age has
been reported by Ramiah et al22 and Lie et al.4 Our data
further suggest increased short-term relative mortality
among younger THR patients with osteoarthritis and those
without previous hospital admissions, indicating that
although THR is a low-risk procedure, it still imposes a risk
that becomes most evident in patients with a low baseline
mortality risk. The increased relative risk among patients
who are young or with a good pre-operative prognostic
profile may reflect patient-related factors such as obesity,
which may be associated with both the development of
osteoarthritis at a young age and an increased procedure-
related risk of adverse outcome, including death, as well as
system-related factors which might include a lower level of
awareness by health professionals towards the prevention,
detection and treatment of thromboembolic complications
in patients considered to have a low risk. Another possible
explanation may be the fact that any surgical procedure
carries a risk which, added to a small baseline risk in these
patients, results in a high relative mortality. It is also possi-
ble that the risk may not be offset by selection among these
low-risk patients, as it may be among those that are high
risk. Although the relative risk was highest for younger
patients, it is important to notice that the absolute mortal-
ity risk was small among these patients.
The mortality for THR patients may be put into clinical
perspective by comparison with mortality among patients
undergoing elective inguinal hernia repair23 or cataract
extraction.24 Both procedures carry an absolute mortality
risk that is lower than that among THR patients, probably
owing to the shorter duration of surgery. Nevertheless, the
relative risk of dying compared with that of subjects not
undergoing these procedures is increased for the youngest
age groups, and decreased afterwards.
Our finding that THR is associated with increased rela-
tive short-term mortality due to myocardial infarction and
venous thromboembolism/pulmonary embolism agrees
with previous observations10,12,25 and was independent of
age and level of comorbidity before the surgery. This
strongly indicates that the prevention and treatment of
thromboembolic events should play a central role when
aiming to reduce or eliminate avoidable deaths following
THR. There is no doubt that target patients should be those
at the highest absolute risk of mortality. Nevertheless, given
the current growth in the number of procedures performed
in young healthy patients,26 as well as the constant broad-
ening of the indication for THR due to increasing expecta-
tions for quality of life,27 more attention needs to be paid to
identifying clinically and financially efficient strategies for
preventing adverse outcomes, including death, following
routine THR among patients with the highest relative risk.
The lower short-term mortality observed among THR
patients with osteoarthritis compared with matched controls
with similar moderate and high comorbidity is likely to be
explained by the careful selection of patients for surgery. This
selection bias is presumably reflected further in the reduced
long-term mortality among all THR patients, results that
agree with previous findings.3,4 However, given the same
selection of patients, it is the negative attributable risk found
in all subgroups of patients, except for young healthy
patients, that could in principle indicate that THR surgery
has a protective effect on mortality. However, a more reason-
able explanation is probably that is is impossible to disentan-
gle the effects of the surgery, patient comorbidity and
selection for surgery on mortality. It is harder to explain why
Table III. Cause-specific 90-day mortality rate ratios (MRRs) with 95% confidence interval (CI) among total hip replacement (THR)
patients with osteoarthritis compared with controls from the general population
Cause of death according to International 
Classification of Disease, Tenth edition 
(ICD-10)*
Osteoarthritis, THR versus general population
0 to 90 days 90 days to 12.7 years
Number of deaths 
(%)†
Adjusted MRR‡ 
(95% CI§) Number of deaths (%)†
Adjusted MRR‡ 
(95% CI)
Myocardial infarction  
(I21.0 to I21.9, I23)
  64 (21)/85 (7)  2.1 (1.5 to 2.9)   6416 (8)/2 093 167 (7)  0.8 (0.8 to 0.9)
Congestive heart failure 
(I11.0, I13.0, I13.2, I50.0 to I50.3, I50.8)
    22 (7)/78 (6)  0.9 (0.9 to 1.5)   5689 (7)/209 152 (7)  0.7 (0.7 to 0.8)
Deep venous thrombosis/pulmonary 
embolism 
(I26, I80.1 to I80.9, I82.1 to I82.9)
  31 (10)/17 (1) 5.7 (3.2 to 10.3)     122 (2)/443 (2)  0.8 (0.6 to 0.9)
Stroke 
(I60 to I69, G45, G46)
  31 (10)/123 (10)  0.8 (0.6 to 1.2)    775 (10)/3002 (10)  0.7 (0.6 to 0.8)
Pneumonia  
(J12.x to J18.x, A481, A709)
  29 (10)/130 (11)  0.8 (0.5 to 1.1)   826 (11)/3474 (12)  0.6 (0.6 to 0.7)
Upper gastrointestinal ulcer 
(K22.1, K25 to K28)
    13 (4)/23 (2)  1.7 (0.9 to 3.4)     119 (2)/394 (1)  0.8 (0.7 to 1.0)
Any cancer 
(C00 to C85, C91 to C95, C88, C90, C96)
    19 (6)/288 (24)  0.2 (0.1 to 0.3) 2110 (27)/6792 (23)  0.9 (0.8 to 0.9)
* both THR patients and controls could have multiple causes of death on the death certificate
† Percentage is calculated as number of deaths within a specific cause divided by the total number of deaths within a particular period
‡ MRR, adjusted for age, gender and Charlson comorbidity index (THR vs general population)
§ CI, confidence interval
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younger THR patients do not follow this pattern. In theory,
these patients may suffer from more severe comorbidities or
the physician may be less prone to record all comorbidities in
younger THR patients than in controls from the general pop-
ulation, but this is hard to prove.
The strengths of our study include large numbers of sub-
jects and the availability of nationwide population-based
medical databases with a documented overall high to mod-
erate data validity.28-30 Data were registered prospectively
and independently of the objective of our study. Follow-up
for mortality was complete, limiting the risk of selection
and information bias. However, our study also has limita-
tions. Assessment of comorbidity was based on routinely
collected data from administrative registries which may be
influenced by coding errors and misclassification of diagno-
ses. However, any misclassification would probably be
independent of THR status. Furthermore, although our
comorbidity data were limited to hospital discharge and
specialist outpatient diagnoses, many of these diagnoses
have previously been validated against medical records,
and the accuracy was found to be more than 90%.31 How-
ever, we had no information on the severity of medical con-
ditions included in the Charlson comorbidity index, factors
that may have introduced residual confounding into our
analyses. Again, however, lack of severity of the comorbid-
ities is most probably independent of THR status. Social
status, drug use and physical activity before surgery and at
follow-up may differ between THR patients and controls,
and at the same time have an effect on mortality, introduc-
ing unmeasured confounding factors. Unfortunately, these
data were not available in our dataset. Only the first pri-
mary THR, registered since the commencement of  the
Danish hip registry, was included. However, according to
the Danish National Registry of Patients, < 1 % of THR
patients and a similar proportion of controls had primary
THR before the Danish hip registry started. Finally, our
study is observational, limiting the possibility of assessing
causation in the association between THR and mortality. 
In summary, THR was associated with lower short- and
long-term mortality among patients with osteoarthritis
than in controls from the general population. However, the
association varied according to age, gender and comorbid-
ity. Younger patients and patients without comorbidity
before surgery have an increase in short-term relative mor-
tality, although the absolute risk among these patients is
small compared with older patients and those with greater
comorbidity because of the lower background mortality. It
is still possible that attention to the care of older patients
and comorbid patients would provide a larger reduction in
mortality. Nonetheless, the patients with the highest rela-
tive mortality risk, younger patients and those without
comorbidity before surgery, may gain most from focused
efforts to prevent potentially avoidable deaths.
The authors wish to thank the orthopaedic surgeons at all hospitals in Denmark
for their co-operation regarding the Registry.
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